Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where did you see exclusivity is 25 years in China? Is that for a Chinese company?
Is the Hikma SCOTUS brief due today?
Each one of us can do our part and write the NY AG, the FTC to complain about the quality of the generic and potential loss of US lives for those that take it to prevent further CVD risk. I plan to have a busy weekend. We need to take the fight to these jerks. Any New Yorkers on the board will get more traction with the NY AG.
Anyone figure out sales growth or decline for Canada? The stocking fee does not provide clarity if sales are growing or not.
Have you sent this link to the FDA to ask if they plan to check the quality of prescription and non prescription fish oil to safeguard the health of Americans? That is within their mission as an agency.
We should all help RAF and send this link to the FDA and ask them about testing.
Thanks for finding this, it might be best to email it to the law firm and let them manage it with Amarin.
Sums up the mindset needed to be an Amarin investor.
The interesting question will be if Reddy launches after the GSK decision is announced and when the judge rules the Delaware case can proceed. Seems to me it will not be worth the risk.
I think Teva and Apotex are no longer bound by the agreement with the loss of the marine patents.
I think a SCOTUS win for Amarin presents max pain for Hikma and that one is 3x all sales and by the time it’s over might amount to $100 plus million.
I don’t have the answers to your questions but thinking along the same lines as to what is at risk for Hikma. I hope one of the board lawyers will correct me but I believe Hikma is looking at a penalty of 3 x total sales with a loss at SCOTUS or rule 60. With Delaware it will be 3x the amount above marine that Amarin can prove. I think with healthnet it might be 3x the reduce it scripts they converted to GV. The suit I am sure that makes Hikma the most nervous is SCOTUS. If GSK prevails in their suit against Teva I think Amarin has solid protection for the Reduce It patents until 2039.
Done
Maybe we can get Bhatt to publish a rebuttal.
That is total garbage from Amarin and I hate how they try to blow off shareholders. All they need to do is add a link to disclaimers in their tweet. Just look how Pfizer and other big pharmaceuticals promote via Twitter. What did they do, hire HS kids to handle their online presence?
And with our luck the legal issues resolve and buyout occurs just when the new taxes hit.
If it does go that way, and it’s just a guess on my part, she ruled based on an egotistical need to set a precedent. This has nothing to do with a political agenda and more to do with her creation of a standard for weighing obviousness....... terrible.
I don’t think we hear a peep until SCOTUS decides whether to hear the case. If they take it she acts and rules in our favor. If they deny she will find a reason to deny our request. Rule 60 is her SCOTUS escape plan.
Until they finally go after all the executives at hedge funds and investment banking firms who cares..... more money for payroll. Let’s go Mets!
Actually Teva and Apotex agreed not to launch as a settlement to their patent litigation but if Hikma/Reddy prevailed in their litigation they would not be bound to the settlement. Teva and Apotex can pursue the marine indication. The fact they have not launched proves supply concerns or that in the current environment, it’s not worth the effort.
If you are a NY Mets fan our owner also holds Amarin. So now I have two reasons to root for my investment...lol.
https://finance.yahoo.com/news/billionaire-steve-cohen-top-10-141809732.html
One of the better articles written about Vascepa without the concluding negative quotes by some of the anti Amarin folks. With 60 my million patients and positive momentum I see the EU as a blockbuster. We will continue to stagnate in this range until we reach a conclusion on the legal matters in the US or sales in the EU quickly outpace the US.
I am not saying it’s bad, I was pointing out based on the footnote the delta between the 203 million and the 154 net may not be all bad debt.
I don't know if this is all bad debt and someone might have to ask the question. A portion might be considered damaged containers, spoilage and such. Also, it depends on how conservative the CFO is and at times you can use the reserve as a cushion for earnings. Higher in one quarter and a bit lower in another. I am not sure based on this we can say 25% is bad debt.
I actually don’t think so, when I got my stents it was a statin, baby aspirin and the addition of Plavix for one year. Vascepa might be a first.
At what point do they try to get this on the label? Every person that receives a stent should also get a Vascepa prescription. I don’t understand why they don’t try to add this in the US, Canada and now EU. For the management of Atherosclerosis, really simple.
I haven’t the slightest idea and just hope we can put an end to this with rule 60 or SCOTUS.
Here it is April, where is Reddy? If Reddy does launch they will wait to see what happens with SCOTUS. I am sure they don't want to be on the hook for infringed sales.
Based on what was posted on this board it looks like May 1 Hikma loses access to UHC and I think someone posted BCBS. Even if nothing falls Amarin's way the US market is worth $600 to $700 million in sales. That has to be added to any buyout and if the RIT patents are good until 2039 that is a nice run on sales.
Too bad we could not ask.....
Can you give shareholders a perspective of the cost should Amarin prevail with the SCOTUS appeal, Nevada rules in favor of shareholders or you have found to infringe on the RIT indication?
They give Amarin attorneys plenty of ammo and just admitted a market share higher than marine.
I do think the strategy was never GIA. Thero and the board looked at a US market with patent protection until 2029 and EU as maximum buyout price. All they needed to do was hit those milestones. We saw them execute a market launch intended to spark some sales while educating doctors on the value of Vascepa. Let the big bio saturate the market with ads. You don’t hire 800 reps with minimal TV advertising if you intend to hit billions in sales. Without the debacle in Nevada they only needed about a year. The Nevada ruling caused a slow walk to the EU hoping an appeal would work.
Now, unless we are willing to accept fire sale prices no big bio is going to buy us until we have positive momentum. They will need to see a fast EU start, or at least a good start with growing sales in Canada and some recovery in the US. Then I think we are ripe for a buyout unless Marjac magic happens or SCOTUS steps in. US patent restoration will bring buyers in a hurry.
Then another stellar work of art by the captain.
Check out this overview created by a Reddit poster. Apologies if this has already been posted.
https://www.reddit.com/r/Amarin/comments/mouvs7/the_multiple_benefits_of_vascepa/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
I thought that was the definition for Kiwi.
Yee had a write up a few weeks ago saying Amarin will lose the US market by the end of 2023, first he is a bull on global sales and now a bear. Analysts suck!
Never fails bought a little more when the price dropped to $5.40 and bought a little today at $5.31 and it never fails that I could buy lower.
I really think this is more a short raid than people or funds bailing.....unless they were JT fans. If you have some spare change, buying even 10 shares means more shares shorts have to buy to cover.
Today is a perfect day to allow one or more BPs to acquire 5% of the company on the open market. It’s a good investment for them and a way to dollar cost average a buyout. Amarin could also pay them to help with US sales.
and this doesn't prohibit a buyout....hopefully we will have an exciting few months where we see
1) Increase in sales
2) News on NASH and COVID
3) GSK prevail over TEVA, Nevada accepts rule 60 and SCOTUS accepts the appeal.
April, May and June will hopefully bring us good news.
Other big happenings.....
EU RIT patents that extend to 2039
Confirmation of US RIT patent to 2039
If your the Hikma CEO you have to be so pissed right now.....
He gets the biggest gift ever using dirty tactics in Nevada, crows to the investment community how much of their swill they will be able to sell and suddenly hits a wall.
Supply constraints and the difficulty in manufacturing puts a stop to grabbing all the RIT scripts at launch. Next, the Delaware suit drives the two largest insurers to basically block any GV scripts. Now he faces some real damages from their lackluster sales if any of the following occur...
1) Rule 60 win
2) Scotus win and here I would say if Scotus takes the case its a win
3) GSK prevails over Teva makes Delaware even more promising
They are really screwed if one or two happens and somewhat in 3. In any case, 1,2 or 3 was not worth it for Hikma. Vascepa may actually cause heart burn for Hikma... Hope this is the lesson that cheaters should never prosper!
It’s same as the way JZ exited after the SPA debacle.
I do think the Nevada action put the nail in the coffin as it pointed out the legal mistakes made by Amarin counsel and lack of follow through. I hope we see a malpractice suit against Covington real soon and Kennedy bounced. I also think the poor sales and marketing strategy was the main reason. Nevada filing was the last straw.
This reply to an Amarin tweet on COVID is both funny and sad:
Jim Trumper Smith
@jimsmit02575033
Replying to
@Amarincorp
Another big cause of death is suicide....likely caused by owning shares of Amarin for years.